Introduction
Methods
-
did not describe original studies
-
described only severity of symptoms or hematological toxicities.
Data analysis
Results
Published papers
Study and patient characteristics
Study | n | Goal | Treatment | Time point | Retrospective/Prospective | Datacollection | References |
---|---|---|---|---|---|---|---|
Bae, 2013 | 300 | Investigate signs and symptoms during temozolomide | Chemotherapy | Treatment | R (cohort) | Medical records on CTCAE version 3.0, grade 1–4 | [32] |
Brada, 2001 | 138 | Investigate efficacy and toxicity of temozolomide in glioblastoma patients | Chemotherapy | Treatment | P (phase II trial) | Medical records on CTCAE, grade 1–4 | [25] |
Cao, 2012 | 112 | Investigate safety and efficacy during chemoradiation vs. radiation in elderly patients | Chemoradiation, radiation (hyofractioned) chemotherapy | Diagnosis, treatment | R (cohort) | Medical records on CTCAE version 3.0, grade 1–5 | [33] |
Chen, 2017 | 712 | Investigate mutant IDH1 and seizures in glioma patients | Diagnosis | R (cross-sectional) | Medical records | [39] | |
Diamond, 2017 | 50 | Investigate prognostic awareness, communication and cognitive function in patients with glioma | All | P | HADS (score 9 or higher) | [26] | |
Ening, 2015 | 233 | Investigate risk factors for glioma therapy complications at diagnosis | Surgery, chemotherapy, chemoradiation, radiation | Treatment | R (cohort) | Medical records | [53] |
Iuchi, 2014 | 121 | Investigate incidence epilepsy in glioma patients | Surgery, chemoradiation | Diagnosis, FU** | R (cohort) | Medical records | [40] |
Jakola, 2012 | 55 | Investigate the association between location, survival, and long-term health in patients with low grade glioma | Surgery, radiation and/or chemotherapy | FU | P | EORTC-BN20 (Likert score 3 and 4) | [27] |
Kerkhof, 2013 | 291 | Investigate seizure control of valproic acid | Anti-epileptics | Diagnosis, All (diagnosis and FU) | R (cohort) | Medical records* | [41] |
Kim, 2013 | 406 | Investigate incidence epilepsy in glioma patients | Surgery, chemoradation, chemotherapy, radiation | Diagnosis, All (diagnosis and FU) | R (cohort) | Medical records* | [42] |
Kocher, 2005 | 81 | Investigate signs and symptoms during chemoradiation | Chemoradiation | Treatment | R (cohort) | Medical records* | [54] |
Koekkoek, 2014 | 178 | Investigate signs and symptoms at end-of life | Palliative care | End-of-life | R (cross-sectional) | Developed symptom questionnaire, completed by physician’s and proxies after patient died | [23] |
Liang, 2016 | 184 | Investigate indidence of epilepsy in supratentorial glioblastoma patients | Surgery, chemotherapy, (intra-tumor) radiotherapy | Diagnosis, FU | R (cohort) | Medical records | [43] |
Malström, 2012 | 291 | Investigate safety and efficacy during chemotherapy vs. radiation in elderly patients | Chemotherapy, (hypofractioned) radiation | Treatment | P (RCT) | WHO grading system for AE grade 2–5; N/V by National Cancer Institute CTC version 2.0 | [28] |
Mamo, 2017 | 64 | Investigate adverse events in glioblastoma patients with bevacizumab | Targeted therapy | Treatment | R (cohort) | Medical records, CTCAE grade 3 and 4 | [34] |
Piribauer, 2003 | 103 | Investigate feasibility and toxicity during lomustine therapy in eldery patients | Chemotherapy | Diagnosis | R (cohort) | Medical records | [44] |
Posti, 2015 | 142 | Investigate presenting symptoms at diagnosis | Diagnosis | R (cohort) | Medical records from emergency rooms, intensive care unit, and different inpatient wards; hospital and imaging referrals, disch letters | [45] | |
Rasmussen, 2017 | 1930 | Investigate symptoms in glioma patients | Surgery | Diagnosis | P (cohort) | Danish Neuro-oncology Registry | [29] |
Russo, 2017 | 527 | Investigate prevalence of headache in glioma patients | Diagnosis | R (cross-sectional) | Face to face interviews | [38] | |
Sagberg, 2013 | 164 | Investigate responsiveness of EQ-5D in glioma patients with surgery | Surgery | Diagnosis | R (cross-sectional) | Medical records | [46] |
Saito, 2014 | 76 | Investigate signs and symptoms during chemoradiation in eldery patients | Chemoradiation, radiation, chemotherapy | Treatment | R (cohort) | Medical records-CTCAE grade 3 and 4 | [35] |
Salmaggi, 2005 | 134 | Set up a registry for glioblastoma patients in Lombardia, Italy | Surgery radiation chemotherapy | Diagnosis | R (cohort) | Medical records-reports on signs/symptoms and seizures | [47] |
Sanai, 2012 | 119 | Investigate surgery associated complications | Surgery | Diagnosis, treatment | R (cohort) | Medical records and telephone interviews | [48] |
Seekatz, 2017 | 54 | Screening for symptom burden in glioma patients | All | P(cohort) | Revised Edmonton Symptom Assessment System (ESAS-r) Score 4–10 | [30] | |
Sizoo, 2010 | 58 | Investigate signs and symptoms at end-of life | Palliative care | End-of-life | R (cohort) | Medical records& charts of nurse specialist on telephone interviews about symptoms based on self-developed checklist | [37] |
Stupp, 2002 | 64 | Investigate toxicity of chemoradation | Chemoradiation plus adjuvant chemotharapy | Treatment | P (cohort) | Medical records - CTCAE version 2.0, grade 3–4 | [31] |
Thrier, 2015 | 57 | Investigate signs and symptoms at end-of life | Palliative care | End-of-life | R (cohort) | Daily reporting of signs and symptoms by standardized protocol | [55] |
Valko, 2014 | 65 | Investigate incidence fatigue after surgery in glioma patients | Surgery | Treatment | P (cohort) | Fatigue Severity Scale (FSS score 4–9), Epworth Sleepiness Scale (ESS score 10 or higher), Hospital Anxiety and Depression Scale (HADS score 10 or higher) | [36] |
Van Breemen, 2009 | 108 | Investigate seizure control of anti-epileptics | Anti-epileptics | Diagnosis, All (diagnosis and FU) | R (cohort) | Medical records | [49] |
Woo, 2014 | 198 | Investigate risk factors for seizures in glioma patients | Surgery, chemoradiation, chemotherapy | Diagnosis, FU | R (cohort) | Medical records | [50] |
You, 2012 | 508 | Investigate incidence epilepsy and postoperative seizure control | Surgery | Diagnosis, FU | R (cohort) | Medical records* | [51] |
Yuile, 2006 | 133 | Investigate signs and symptoms during radiotherapy | Radiation | Diagnosis | R (cohort) | Medical records | [52] |
Study | N | M/F | Age (year) Mean range | KPS (%) (Mean) | KPS ≥ 70% | Glioma WHO II (n) | Glioma WHO III (n) | Glioma WHO IV (n) | Median OS (months) range | References |
---|---|---|---|---|---|---|---|---|---|---|
Bae, 2013 | 300 | 187/113 | 49 17–84 | 87 | 20 | 67 | 213 | [32] | ||
Brada, 2001 | 138 | 85/53 | 54 24–77 | 100% (KPS > 70%) | 138 | [25] | ||||
Cao, 2012 | 112 | 73/39 | 70 60–86 | 80 | 0 | 0 | 112 | 7 | [33] | |
Chen, 2017 | 712 | 400/312 | 55 | 77 | 128 | 507 | [39] | |||
Diamond, 2017 | 50 | 34/16 | 50 18–77 | 16 | 34 | [26] | ||||
Ening, 2015 | 233 | 117/116 | 58 | 79% (KPS > 70%) | 0 | 0 | 233 | 9.5 0–72 | [53] | |
Iuchi, 2014 | 121 | 74/47 | 58 | 19 | 21 | 81 | [40] | |||
Jakola, 2012 | 55 | 30/25 | 41 | 91% (KPS ≥ 80%) | 55 | [27] | ||||
Kerkhof, 2013 | 291 | 169/122 | 60 24–85 | 0 | 0 | 291 | 13 | [41] | ||
Kim, 2013 | 406 | 244/162 | 51 18–86 | 75% (KPS > 70%) | 0 | 124 | 282 | [42] | ||
Kocher, 2005 | 81 | 53/28 | 52 15–72 | 83 | 12 | 22 | 47 | [54] | ||
Koekkoek, 2014 | 178 | 125/53 | 60 | 20%3 m 2%1 w | 0 | 19 | 159 | 12.4 gr III 10.6–14.1 10.6 gr IV 9.2–12.1 | [23] | |
Liang, 2016 | 184 | 100/84 | 49 20–69 | 47 e 56 we | 184 | [43] | ||||
Malström, 2012 | 291 | 173/118 | 70 | 0 | 0 | 291 | 8.3 chemo 6.0 rt 7.5 hypofr rt | [28] | ||
Mamo, 2017 | 64 | 40/24 | 54 26–83 | 88% | 64 | [34] | ||||
Piribauer, 2003 | 103 | 65/38 | > 55 55–83 | 79 | 0 | 0 | 103 | 17.5 py 8.6 pe | [44] | |
Posti, 2015 | 142 | 76/66 | 60 | 29 | 31 | 82 | [45] | |||
Rasmussen, 2017 | 1930 | 1158/772 | 18–79 | 247 | 279 | 1364 | [29] | |||
Russo, 2017 | 527 | 314/213 | 53 | 139 | 87 | 268 | [38] | |||
Sagberg, 2013 | 164 | 56 | 73 | 43 | 121 | [46] | ||||
Saito, 2014 | 76 | 50/26 | 47 py 71 pe | 82% py 70% pe | 0 | 0 | 76 | 15.2 12.9–18.5 21.6 py 15.6 pe | [35] | |
Salmaggi, 2005 | 134 | 82/52 | 61 | 85% | 0 | 0 | 134 | [47] | ||
Sanai, 2012 | 119 | 45 18–81 | 75 | 34 | 23 | 62 | [48] | |||
Seekatz, 2017 | 54 | 60 24–79 | 54 | [30] | ||||||
Sizoo, 2010 | 58 | 39/19 | 52 18–81 | 0 | 15 | 41 | 21 gr III 11–86 12 gr IV 0.5–71 | [37] | ||
Stupp, 2002 | 64 | 39/25 | 52 24–70 | 64% (KPS > 80%) | 64 | 23 | [31] | |||
Thrier, 2015 | 57 | 39/18 | 59 | 30 | 0 | 0 | 57 | 12 | [55] | |
Valko, 2014 | 65 | 44/21 | 57 | 80 | 0 | 0 | 65 | [36] | ||
Van Breemen, 2009 | 108 | 54/54 | 40 53 | 33 | 75 | > 8 years HGG 19 LGG | [49] | |||
Woo, 2014 | 198 | 122/76 | 55 18–88 | 81% | 125 | 73 | 9.0 11.0 gr III 8.0 gr IV | [50] | ||
You, 2012 | 508 | 306/202 | 38 16–72 | 88% (KPS ≥ 80%) | 508 | 0 | 0 | 32.9 12–58.3 | [51] | |
Yuile, 2006 | 133 | 84/49 | 59 22–86 | 0 | 0 | 133 | 10 0.1–51.8 | [52] |
Symptom prevalence throughout the disease course
Most prevalent symptoms
Seizures (1) | Cognitive deficits (2) | Drowsiness (3) | Dysphagia | Headache | Confusion(4) | Aphasia (5) | Motor deficits (6) | Fatigue (7) | Dyspnea (8) | Nausea/vomiting (9) | Urinary incontinence (10) | Pain (11) | Anxiety/depression (12) | Anorexia (13) | Sensory deficits | Dizziness (14) | Visual deficits (15) | Gait disturbance | Alopecia | Skin problems (16) | Right left confusion | Constipation | Diarrhea | Dyspepsia | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total disease trajectory | 36.5 | 35.9 | 35.3 | 30.0 | 27.2 | 26.5 | 23.7 | 21.4 | 20.3 | 19.6 | 19.0 | 16.5 | 15.5 | 15.1 | 13.5 | 13.3 | 13.0 | 12.1 | 10.0 | 8.1 | 6.7 | 5.0 | 4.3 | 2.6 | 2.0 |
Diagnostic phase | 34.7 | 36.0 | 15.0 | 4.0 | 30.5 | 20.1 | 21.6 | 6.5 | 13.3 | 23.5 | 6.7 | 10.0 | |||||||||||||
Treatment/FU phase | 36.7 | 18.3 | 7.7 | 7.7 | 3.0 | 8.4 | 10.5 | 13.7 | 23.2 | 7.5 | 6.8 | 12.7 | 5.9 | 12.8 | 8.1 | 5.2 | 5.0 | 3.8 | 2.6 | 2.0 | |||||
End-of-Life phase | 44.6 | 44.3 | 81.3 | 41.9 | 37.3 | 40.3 | 48.0 | 44.2 | 49.9 | 17.7 | 19.2 | 37.0 | 15.2 | 15.8 | 2.0 | 23.0 | 22.0 | 9.0 |
Symptom prevalence per phase
Symptom prevalence by tumor grade
Study | Histological grade glioma | ||
---|---|---|---|
WHO II | WHO III | WHO IV | |
Seizures | |||
Iuchi | 47% pr 74% t | 29% pr 67% t | 20% pr 57% t |
Kim | 34–37% | 29% | |
Posti | 83% | 65% | 38% |
Van Breemen | 70% pr 76% t | 52% pr 80% t | |
Rasmussen | 58% pr | 45% pr | 24% |
Cognitive disorders | |||
Posti | 21% | 45% | 74% |
Rasmussen | 24% | 41% | 48% |
Headache | |||
Rasmussen | 22% | 30% | 38% |